MedTrace Logo

Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002)

NCT06829225 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-02-17

No results posted yet for this study

Summary

The goal of this study is to learn about the safety of tulisokibart in healthy participants and what happens to tulisokibart over time when participants receive treatment intravenously versus subcutaneously.

Conditions

  • Colitis, Ulcerative

Interventions

DRUG

Tulisokibart

SC Injection or IV Infusion

DRUG

Placebo

Tulisokibart-matched Placebo SC Injection or IV Infusion

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-13
Primary Completion
2024-11-11
Completion
2024-11-11
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06829225 on ClinicalTrials.gov